AstraZeneca has, however, held on to anifrolumab, a late-stage phase 3 candidate being developed for the severe autoimmune disease lupus. "Autoimmune diseases represent one of the largest unmet ...

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

AstraZeneca has completed the resurrection of its anifrolumab drug for systemic lupus erythematosus (SLE) after claiming FDA approval for the drug as an add-on therapy for adults with the ...

Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which manufactures anifrolumab and funded the study.

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

Anifrolumab patients also had a 61% lower risk of having their organ damage get worse, results show. The study was paid for by AstraZeneca, which manufactures Saphnelo.

Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...